Oragenics, Inc. (NYSEAMERICAN:OGEN) Sees Large Decline in Short Interest

Oragenics, Inc. (NYSEAMERICAN:OGEN) was the recipient of a large decline in short interest in August. As of August 31st, there was short interest totalling 2,130,000 shares, a decline of 41.3% from the August 15th total of 3,630,000 shares. Based on an average daily volume of 5,910,000 shares, the short-interest ratio is presently 0.4 days. Approximately 1.9% of the company’s shares are short sold.

Shares of OGEN traded down $0.02 during trading hours on Friday, reaching $0.64. 914,244 shares of the company traded hands, compared to its average volume of 11,764,723. The firm has a fifty day moving average price of $0.45. The stock has a market cap of $74.02 million, a P/E ratio of -3.03 and a beta of 0.19. Oragenics has a 12 month low of $0.38 and a 12 month high of $1.80.

Oragenics (NYSEAMERICAN:OGEN) last announced its earnings results on Monday, August 16th. The biotechnology company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01.

Several institutional investors and hedge funds have recently made changes to their positions in OGEN. BlackRock Inc. boosted its stake in shares of Oragenics by 124.1% during the 1st quarter. BlackRock Inc. now owns 1,581,463 shares of the biotechnology company’s stock valued at $1,434,000 after purchasing an additional 875,639 shares in the last quarter. Geode Capital Management LLC boosted its stake in Oragenics by 131.3% during the first quarter. Geode Capital Management LLC now owns 535,519 shares of the biotechnology company’s stock worth $485,000 after acquiring an additional 303,950 shares in the last quarter. Northern Trust Corp boosted its stake in Oragenics by 205.4% during the first quarter. Northern Trust Corp now owns 181,383 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 121,992 shares in the last quarter. Jane Street Group LLC bought a new stake in Oragenics during the first quarter worth about $30,000. Finally, Citadel Advisors LLC boosted its stake in Oragenics by 77.2% during the first quarter. Citadel Advisors LLC now owns 370,521 shares of the biotechnology company’s stock worth $336,000 after acquiring an additional 161,437 shares in the last quarter. 8.05% of the stock is currently owned by hedge funds and other institutional investors.

Oragenics Company Profile

Oragenics, Inc develops antibiotics for infectious diseases in the United States. Its lead product candidate under development is OG716, an antibiotic for the treatment of Clostridium difficile. The company also engages in the development and commercialization of Terra CoV-2, a vaccine product candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

See Also: Call Option

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.